ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿

Service Background

With the rapid development of the pharmaceutical industry, the demand for innovative drugs and technologies is growing. CMC Services of Huace Pharmaceuticals keeps pace with the market and launches related technology transfer services: Tacrolimus Sustained Release Capsules and Olopatadine Hydrochloride Eye Drops. These services provide all-round technical support from raw material optimization to formulation development, helping customers quickly enter the market and meet patient needs.

1. Tacrolimus sustained-release capsules
Generic name: Tacrolimus
Indications: Prevention of rejection after kidney and liver transplantation, treatment of rejection that is ineffective with other immunosuppressive drugs.
Dosage form: 0.5mg, 1mg
Usage and dosage: Once a day, take in the early morning. Take it on an empty stomach, at least 1 hour before or 2 ~3hours after food.
Reference preparation: Tacrolimus sustained-release capsules, Astellas, Advagraf®/Sinograf®
Marketing status: 2007 (Europe), 2010 (China)
Patent status: expired in 2019, no patent research and development risk
Registration category: New Class 4 application
Medical insurance status: Class B medical insurance

2. Olopatadine hydrochloride Eye Drops
Generic name: Olopatadine
Indications: Allergic conjunctivitis
Dosage form: Multiple doses 0.2%
Usage and dosage: Use once a day
Marketing status: Launched in China in 2022
Patent status: No patent restrictions
Registration category: New 4 categories

Our advantages

Committed to providing customers with efficient and reliable technical support to help customers quickly enter the market and meet patient needs;

Services cover the entire process from raw material optimization to formulation development to ensure product quality and performance;

Whether it is organ transplantation or allergic conjunctivitis treatment, it can provide comprehensive solutions to help the development of the pharmaceutical industry.

Service process